A Phase 4 interventional study of Doxycycline and Placebo in Rosacea, sponsored by Galderma R&D. Completed at 10 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-08-01.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing doxycycline in Rosacea — none open to participants now, 1 under way, none of them phase 3. Doxycycline · Rosacea.
Among the 12 studies testing doxycycline in Rosacea, this one is the 5th largest by enrollment, is one of 2 that started in 2011, is one of 6 in phase 4, and was the 5th registered.
233 studies on the registry are indexed under Rosacea; 22 are open to participants now.
Browse Rosacea studies →None of the 12 studies testing doxycycline in Rosacea is open now. The open studies under Rosacea, anywhere →
Doxycycline: first FDA approval 1967 (VIBRAMYCIN). What it is approved for, and how studies give it, is on its page →
Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2011.
This study's enrollment of 170 is above the median of 61 across 200 interventional studies indexed under Rosacea.
Median enrollment 150 across the 12 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 7 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
28 studies in Rosacea by Galderma Group AG: none open now, none under way, none of them phase 3. Of 28 finished, 21 (75%) have results posted.
Among the 28 studies in Rosacea by Galderma Group AG, this one is the 14th largest by enrollment of the 24 interventional ones that give a count, is one of 7 that started in 2011, is one of 9 in phase 4, and was the 10th registered.
Galderma Group AG’s Rosacea studies by the year they started, since 2002.
1 of the studies testing doxycycline in Rosacea that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04108897Johns Hopkins UniversityAnalysis of the Microbiome in Rosacea | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing doxycycline in Rosacea, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 28 in Rosacea:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to determine the clinical effects of doxycycline 40 mg (30 mg immediate release and 10 mg delayed release beads) capsules (Oracea®) as compared to placebo in the skin of adults with papulopustular rosacea and to identify a correlation, if any, with rosacea-related inflammatory markers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules
Drug: Doxycycline
placebo
Other: Placebo
doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules, oral, one capsule daily in the morning
Also known as: Oracea®
Placebo, oral, one capsule daily in the morning
Change From Baseline in Inflammatory Lesion Counts
Mean change in inflammatory lesion counts from baseline to week 12
Time frame: baseline to week 12
Change From Baseline in Biochemical Markers of Rosacea From Tape Stripping and/or Skin Biopsy From Baseline to Week 12
Mean change from baseline to week 12 in biochemical markers of rosacea and expression in skin samples. A biological marker is a substance used as an indicator of a biological state such as rosacea. Biochemical markers are serine protease activity and expression, metalloprotease activity and expression, and production of leucine leucine-37 \[LL-37\] peptide.
Time frame: baseline to week 12
Investigator's Global Assessment (IGA) Scores at Week 12
Number of participants in each category of the Investigator's Global Assessment (IGA) scores at week 12. Investigator's Global Assessment evaluates papules and pustules of rosacea on a scale from 0 - 4 (0 = Clear, 1 = Near Clear, 2 = Mild, 3 = Moderate and 4 = Severe) with 0 being best and 4 being worst.
Time frame: Week 12
Change From Baseline in Clinician's Erythema Assessment (CEA) Scores
Mean change in Clinician's Erythema Assessment (CEA) from baseline to week 12. Clinician's Erythema Assessment evaluates erythema on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Significant and 4 = Severe) with 0 being best and 4 being worst.
Time frame: baseline to week 12
First subject enrolled 9 May 2011, last subject last visit 2 July 2012
| Milestone | Oracea® | Placebo Capsules |
|---|---|---|
| Started | 84 | 86 |
| Completed | 77 | 83 |
| Not completed | 7 | 3 |
Mean change in inflammatory lesion counts from baseline to week 12
| inflammatory lesions | Oracea® | Placebo |
|---|---|---|
| Change From Baseline in Inflammatory Lesion Counts | -4.3 ± 7.9 | -3.2 ± 8.6 |
Mean change from baseline to week 12 in biochemical markers of rosacea and expression in skin samples. A biological marker is a substance used as an indicator of a biological state such as rosacea. Biochemical markers are serine protease activity and expression, metalloprotease activity and expression, and production of leucine leucine-37 \[LL-37\] peptide.
| micr grams protein | Treatment Success | Treatment Failure |
|---|---|---|
| Cathelicidin | -0.0931 ± 0.5491 | -0.0379 ± 0.1545 |
| KLK5 | -0.0034 ± 0.0110 | -0.0049 ± 0.0146 |
| MMP9 | -0.0017 ± 0.0100 | -0.0021 ± 0.0233 |
| Total Protease | -22351.6 ± 102888.2 | -22540.9 ± 66146.2 |
Number of participants in each category of the Investigator's Global Assessment (IGA) scores at week 12. Investigator's Global Assessment evaluates papules and pustules of rosacea on a scale from 0 - 4 (0 = Clear, 1 = Near Clear, 2 = Mild, 3 = Moderate and 4 = Severe) with 0 being best and 4 being worst.
| participants | Oracea® | Placebo |
|---|---|---|
| Clear | 8 | 2 |
| Near Clear | 23 | 18 |
| Mild | 35 | 31 |
| Moderate | 12 | 20 |
| Severe | 6 | 15 |
Mean change in Clinician's Erythema Assessment (CEA) from baseline to week 12. Clinician's Erythema Assessment evaluates erythema on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Significant and 4 = Severe) with 0 being best and 4 being worst.
| units on a scale | Oracea® | Placebo |
|---|---|---|
| Change From Baseline in Clinician's Erythema Assessment (CEA) Scores | -1.0 ± 2.9 | -0.8 ± 3.1 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oracea® | — | 2/84 (2.4%) | 8/84 (9.5%) |
| Placebo | — | 0/86 (0%) | 6/86 (7%) |
| Event | Oracea® | Placebo |
|---|---|---|
| Chest painCardiac disorders | 1/84 | 0/86 |
| Spontaneous abortionPregnancy, puerperium and perinatal conditions | 1/84 | 0/86 |
| Event | Oracea® | Placebo |
|---|---|---|
| nauseaGastrointestinal disorders | 3/84 | 1/86 |
| sinusitisInfections and infestations | 3/84 | 2/86 |
| upper respiratory infectionInfections and infestations | 2/84 | 3/86 |
| Age, Continuous(years) | Oracea® | Placebo | Total |
|---|---|---|---|
| Mean | 49.6 ± 11.4 | 48.7 ± 10.8 | 49.1 ± 11.1 |
| Sex: Female, Male(Participants) | Oracea® | Placebo | Total |
|---|---|---|---|
| Female | 61 | 60 | 121 |
| Male | 23 | 26 | 49 |
| Region of Enrollment(participants) | Oracea® | Placebo | Total |
|---|---|---|---|
| United States | 84 | 86 | 170 |
The record gives a start of Apr 2011, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doxycycline